Clover Health Investments Analyst Price Targets

Wall Street analyst price targets and consensus rating for Clover Health Investments (CLOV).

Price Target Range — 7 Quarters

Analyst Consensus — 4 Analysts

2Buy

2Hold

Consensus RatingBuy# Analysts4Avg. Consensus PT$5Upside to Avg. PT+1.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 6, 2026	UBS	Jonathan Yong	PT Raise	Neutral	$5→$5
Jul 21, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$4→$6
Jun 11, 2026	UBS	Jonathan Yong	PT Raise	Neutral	$3→$5
Jun 4, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$3→$4
Mar 20, 2026	Canaccord Genuity	Richard Close	PT Cut	Buy	$4→$3
Mar 5, 2026	Leerink Partners	Whit Mayo	PT Cut	Market Perform	$3→$3
Jan 20, 2026	Canaccord Genuity	Richard Close	Maintained	Buy	$4
Nov 6, 2025	Canaccord Genuity	Richard Close	PT Cut	Buy	$4→$4
Aug 7, 2025	Canaccord Genuity	Richard Close	PT Cut	Buy	$5→$4
Aug 6, 2025	UBS	Jonathan Yong	PT Cut	Neutral	$5→$3
Mar 3, 2025	Canaccord Genuity	Richard Close	PT Raise	Buy	$4→$5
Dec 17, 2024	Craig-Hallum	Matt Hewitt	Initiate	Buy	$6
Oct 7, 2024	UBS	Jonathan Yong	Initiate	Neutral	$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5

UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $4.75 to $5.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and raises the price target from $4.2 to $5.5.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $4.75

UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $2.75 to $4.75.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $4.2

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and raises the price target from $3.2 to $4.2.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Lowers Price Target to $3.2

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and lowers the price target from $3.7 to $3.2.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Maintains $3.7 Price Target

Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and maintains $3.7 price target.

Benzinga Newsdesk

Clover Health Investments Corp

ニュース

パートナーシップ

ベンジンガ・グローバル

Clover Health Investments Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $4.75

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $4.2

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Lowers Price Target to $3.2

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Maintains $3.7 Price Target

People Also Watch

People Also Watch

Clover Health Investments Corp

ニュース

パートナーシップ

ベンジンガ・グローバル

Clover Health Investments Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5

PROCanaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5

PROUBS Maintains Neutral on Clover Health Investments, Raises Price Target to $4.75

PROCanaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $4.2

PROCanaccord Genuity Maintains Buy on Clover Health Investments, Lowers Price Target to $3.2

PROCanaccord Genuity Maintains Buy on Clover Health Investments, Maintains $3.7 Price Target

People Also Watch

People Also Watch

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5

PRO
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $4.75

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $4.2

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Lowers Price Target to $3.2

PRO
Canaccord Genuity Maintains Buy on Clover Health Investments, Maintains $3.7 Price Target